a2z Radiology AI vs Medable
Side-by-side comparison of AI visibility scores, market position, and capabilities
a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.
About
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.
Medable raised $304M to build the leading decentralized clinical trial (DCT) platform, enabling remote patient participation, eConsent, and wearable data integration for pharmaceutical trials.
About
Medable provides the technology infrastructure for decentralized clinical trials (DCTs) — enabling pharmaceutical companies to conduct trials where patients participate from home rather than traveling to research sites. The platform covers the full DCT workflow: electronic informed consent (eConsent), remote patient monitoring via wearables, telemedicine visits, electronic clinical outcome assessments (eCOA), and direct-to-patient drug delivery coordination.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.